While Haemonetics Corp has overperformed by 2.32%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, HAE rose by 7.34%, with highs and lows ranging from $85.61 to $47.31, whereas the simple moving average jumped by 31.76% in the last 200 days.
On August 11, 2025, Raymond James Downgraded Haemonetics Corp (NYSE: HAE) to Outperform. A report published by Barrington Research on August 08, 2025, Reiterated its previous ‘Outperform’ rating for HAE. JP Morgan also Downgraded HAE shares as ‘Neutral’, setting a target price of $62 on the company’s shares in a report dated August 08, 2025. Robert W. Baird initiated its ‘Outperform’ rating for HAE, as published in its report on June 26, 2025. BofA Securities’s report from February 07, 2025 suggests a price prediction of $68 for HAE shares, giving the stock a ‘Underperform’ rating. JP Morgan also rated the stock as ‘Overweight’.
Analysis of Haemonetics Corp (HAE)
Further, the quarter-over-quarter decrease in sales is -5.27%, showing a negative trend in the upcoming months.
Haemonetics Corp’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of 19.47% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.03, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and HAE has an average volume of 973.37K. On a monthly basis, the volatility of the stock is set at 3.90%, whereas on a weekly basis, it is put at 2.19%, with a gain of 3.79% over the past seven days. Furthermore, long-term investors anticipate a median target price of $84.55, showing growth from the present price of $83.81, which can serve as yet another indication of whether HAE is worth investing in or should be passed over.
How Do You Analyze Haemonetics Corp Shares?
Medical Devices giant Haemonetics Corp (HAE) is based in the USA and is one of the largest companies in the market. When comparing Haemonetics Corp shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 24.45, there is a growth in quarterly earnings of 22.93%.
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.60%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 111.23% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
